THIS SHARE WILL BE WORTH 3.00 IN 2009

Hi Parthus,

I think we all agree re the rocky ride.
Companies such as PTI never have a smooth ride, it's the way of the bio/drug type products.

I saw a paper the other day on a companies product trials, (a medical probe) it was 166 full AA pages long.
This was on a fairly simple device. It makes you wonder just how much written evidence is required from first submission to final acceptance of something more complex like a drug. No wonder it takes so long from concept to fruition.

Cheers Greek.

Looks like AXA have increased their holdings a bit, 318,221 added. Can't be bad

Greekman,

I will take any news as positive.

We are badly falling behind the broader market.

Then again even Glaxo got had a hard time today.

I dont see any major movement until the FDA report early next year.
I will sit on my hands till then.

Transco

Just read your post of 1yr ago trans. "Just keep your nerve". It's the same story for this year. I Feel patience will be rewarded handsomely. I'm also happy to hold for the medium term. Regards Parthus.

Parthus,

Nice one chum!!!

I should have remembered!!

Thanks for the thought!!

Things progressing in yet another drug. As with most such progress, this will move very slowly, but it shows PTI are always looking forward. Their R@D must be an envy of most similar market cap bio companies.

This new trial is in an area I'm not unfamiliar with. Xenova were running a similar trial on non-operable,re-occuring brain tumours of this nature. The cytotoxic agent was administered directly into the tumour site via a catheter. Unfortunately XEN was swallowed up by a parisitic buyout group. The encouraging point is pti's solid pipeline and stronger financials should carry them further.

I dont think there is a lot to this story chaps. Suspect that the company broker is looking for any good news they can find to prop up a failing share price.
Sorry to be negative but just my opinion!

Yeah it's gonna be a long drawn out story!

Blood Pressure Vaccine In Existence
Written by OJ Fagbire
Sunday, 13 May 2007

Protherics, a British drug company based in Cheshire, claims to have developed and tested a vaccine that will help people control their blood pressure levels. According to the firm, the vaccine has been extensively tested and should be released to the general public within the next half decade.

With high blood pressure being one of the fastest growing killers world wide, Protherics could have another long time winner on their books.
Again not one for the short term, but a possible winner in 4 to 5 years.

Exactly jam tomorrow - come on PTI lets see something concrete for once.
Who's the broker in charge - tell the story generate interest!!!!!!!!

Hi Transco,

The thing is with bio type companies, the jam is never now, due to the complexity and time scale for trials of such products.
Protherics are going from strength to strength at a nice pace.
It has never been a blue sky tomorrow share but an investment for the future.
This company are not one for putting out pure hype. Their releases contain good content.

Over the next 12 months there are sure to be updates re several of their products.

If you are looking at a bottom drawer share, this is the one.

A good day yesterday, at at the moment the sp is nicely higher, all on fairly low volume with buys not that much more than sells, which leads me to think a largish order is being filled.

A release soon perhaps of an institutional buy?

All IMHO of course.

Agree - this is old news recirculated...maybe not by the broker...perhaps the writer needed some spending money for the Bank Hol at the end of May (wash my mouth!)
This co has a Pipeline and Cash is coming in, so the current sp is "probably" about right....the "BP-drug" is starting trials (PhII) later this year'07 and we shall have to wait a while for the results....probably 2009

Another angle is that the Government is considering changing the Rules re NHS private medicine - at present if you want a non-approved treatment you have to go private (ie pay for everything)...there is a suggestion that folk would be prepared to pay for "the drug" if they had the treatment in their local NHS hospital....it might be a way to satisfy popular expectations of ever-more expensive treatments. That being so, this story might just turn the Minister's mind as the expected demand is likely to be great - if it does not have the usual (unfortunate) side-effect that Gentlemen would not prefer.
Therefore I suspect "this story" is all to do with the NHS ...and NOT Protherics, or their MM, trying to lift the sp.

Here we go again down!
Lower than a snakes belly.
This must be the most frustrating share on the market.

no,CeNeS [cen] is !

Looking at the share price over the last couple of weeks, it is obvious that the news released today had obviously leaked.
The thing is how much has this been priced into the sp.
Not good. But with bio/drug companies knocks such as these are to be expected.
I see a 10% drop before the sp picks up again.

Protherics said it has agreed to provide additional manufacturing and stability data requirements to support a Biologicals License Application for its Voraxaze in the US, following its recent successful talks with the FDA. The FDA has also agreed to Protherics resubmitting its application as a rolling submission, starting in early 2008.

Protherics will continue to supply Voraxaze on a named patient basis in Europe for intervention use in patients at risk of severe or life-threatening methotrexate (anti-cancer agent) toxicity, the biopharmaceutical company said.

Separately, the company said it presented 'encouraging' OncoGel phase 2a oesophageal cancer data at a US conference and that it is planning to undertake a phase 2b study of the product in combination with chemoradiotherapy in patients in the second half of 2007.

Always good to see an institution increase their holdings a few days prior to results.
They could also be taking advantage of the sp reduction over the last couple of weeks. Still if they thought the sp would drop after tomorrow, they would had held off buying till then. Let's hope they got it right.

Results.

Revenues up 31.1 mill from 17.7 mill.
Profits (gross) 19.8 mill from 6.4 mill

Research/development, big increase.
Year loss less than market expectations at 3.6 mill down from 9.6 mill

Cash up to 40 mill from 9.6 mill.

Progress looking good in all areas, apart from the recent hiccup we all know about.

All in all a good year for Protherics, with future prospects looking excellent.

Although early I would have expected more trades and a rise in the SP by now.
No doubt many are looking at the cash increase as being mainly from the fund raising, instead of the bottom line.
Protherics are cash strong with the present cash burn not putting the company at risk.
It looks as if many were expecting the results to be better re more jam today (now) but drug, bio type companies don't work like this.
Still expect the institutions to increase their holdings.